Johnson & Johnson to Present New Data for TECNIS Odyssey, The Fastest Growing PCIOL in the U.S^, at ASCRS 2025

News provided by

Apr 25, 2025, 08:00 ET

Robust data evaluating TECNIS Odyssey demonstrates outstanding patient outcomes with the new intraocular lens

J&J to be included in 22 abstracts evaluating research, clinical, and patient reported outcomes

JACKSONVILLE, Fla. , April 25, 2025 /PRNewswire/ -- Johnson & Johnson, a global leader in eye health, will present data supporting the performance of the next-generation TECNIS Odyssey IOL at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, March 25-28 in Los Angeles, CA. Four of the 22 company sponsored and investigator led studies report excellent visual outcomes at every distance, minimized dysphotopsias, and high spectacle independence with TECNIS Odyssey IOL, further supporting the product's position as the fasting growing PCIOL in the U.S. market^{^}. Additional research being presented also reports positive visual and refractive outcomes associated with TECNIS Eyhance, and suggests that TECNIS Symfony OptiBlue provides mild glaucoma patients the opportunity to enjoy good vision at all distances. A full list of the abstracts can be found here.

"TECNIS Odyssey consistently delivers superior image contrast*¹²³and unmatched range of vision^**¶45 offering our patients outstanding visual outcomes, while giving surgeons higher tolerance to refractive error⁺⁶. We're ecstatic to share data that affirms this at ASCRS 2025, while also offering ophthalmologists opportunities to hear how their peers optimize patient outcomes with TECNIS Odyssey and elevate their practice with our advanced surgical solutions," said Erin Powers, Vice President North America, Surgical Vision, Johnson & Johnson.

Key Data Highlighting the TECNIS Family of Premium IOLs:

Patient Reported Outcomes and Visual Acuity after Bilateral Implantation of a Next Generation Presbyopia Correcting Intraocular Lens; Brunson, OD, Hacopian, MD. (Abstract #107160)
- Interim results from clinical evaluations of patients bilaterally implanted with TECNIS Odyssey at least three months postoperative suggest:
  - Excellent visual outcomes at distance, intermediate, and near,
  - Minimal issues with dysphotopsias, and
  - High spectacle independence.

Real-World Evidence Visual Outcomes of a Full Visual Range Intraocular Lens; Priya M. Mathews, MD. (Abstract #109977)
- A review of real-world evidence of patients bilaterally implanted with TECNIS Odyssey IOL suggests:
  - Full range of distance to near visual performance,
  - None to minimal visual symptoms typically associated with PCIOLs, and
  - A high rate of postoperative spectacle independence.

Visual Outcomes and Refractive Tolerance of Advanced Monofocal IOLs in Post-Refractive Eyes; Thenappan, MD, Wiley, MD, et. Al. (Abstract #110744)
- The retrospective observational study of eyes implanted with TECNIS Eyhance post refractive surgery showed:
  - Good visual and refractive outcomes,
  - Low rate of enhancements post-surgery, and
  - Good distance vision.

Clinical Outcomes in Patients with Mild Glaucoma Following Implantation of Violet Light-Filtering, Extended Depth of Focus IOLs; Vendal, MD. (Abstract #108071)
- An observational study evaluating clinical and patient-reported outcomes following bilateral implantation of TECNIS Symfony OptiBlue in patients diagnosed as glaucoma suspects or mild glaucoma found:
  - All subjects were 20/30 or better at all distances,
  - Spectacle independent at all distance and intermediate,
  - Suggesting violet-light filtering EDOF IOLs can provide glaucoma patients with the opportunity to enjoy good vision at all distances.

Peer to Peer Educational Events

To further support ophthalmologists in pursuit of better outcomes for patients and to help empower them to elevate their practices, Johnson & Johnson is hosting educational sessions with key opinion leaders throughout the weekend:

Booth Talks: "A Modern Practice: Hear from your Peers"

Elevate your IOL Portfolio: Leverage the Strength of the TECNIS Platform with Carmen Canovas, PhD; Daniel Chang, MD; Eric Donnenfeld, MD - Saturday, April 26, 10-10:20AM
Elevate your game: Delivering patient value to grow your practice with Eva Liang, MD; Taylor Strange, DO - Saturday, April 26, 2-2:20PM
Elevate your practice: Deliver the complete premium experience with Catalys COS7.0 with Sachar Tauber, MD; Ravi Patel, MD - Sunday, April 27, 10-10:20AM

Tap Room Event: TECNIS Odyssey: Maximizing Outcomes with the fastest growing PCIOL in the US^{^} with Drs. Blake Williamson, Niraj Desai, Caroline Watson and Luke Rebenitisch - Saturday, April 26 from 12:00-1:00pm in the ASCRS Tap Room.

Lunch Symposium: Maximizing Outcomes with TECNIS Odyssey Full Visual Range IOL^* with Drs. Vance Thompson, Karolinne Rocha, Francis Mah and Joaquin de Rojas - Saturday, April 27 from 12:00-1:00pm in Room 408AB.

More information on the peer to peer events can be found here, and Johnson & Johnson can be found at booth #1439.

All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve, or recommend the use of any products, devices, or services.

Please be advised that information such as your name and the value and purpose of any educational item, meal or other items of value you receive may be publicly disclosed, as required by law. If you are licensed in any state or other jurisdiction or are an employee or contractor of any organization or governmental entity that limits or prohibits meals from pharmaceutical and medical device companies, please identify yourself so that you (and we) are able to comply with such requirements. We regret that we are unable to offer food or drink to GOVERNMENT EMPLOYEES as well as VERMONT health care professionals. We also ask that if your employer or local government has policies or laws that impact the provision of this meal that you honor all such restrictions. Industry Codes of Ethics limit attendance at corporate sponsored events to healthcare professionals with a bona fide professional interest in the programs. Because Johnson & Johnson is committed to following these codes, spouses or significant others should not attend this event. Thank you for being understanding of the changes within the healthcare industry.

About Vision at Johnson & Johnson

Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients' eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionizing the way people see and experience the world. Visit us at clearvisionforyou.com, follow @JNJVision on Twitter, Johnson & Johnson | Vision on LinkedIn, and @JNJVision on Facebook. Johnson & Johnson Surgical Vision, Inc. is part of Johnson & Johnson MedTech.

About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding TECNIS Odyssey. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Surgical Vision, Inc. Risks and uncertainties include, but are not limited to competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

©Johnson & Johnson and its affiliates 2025. All rights reserved.
^ Based on Market Scope's estimated procedure for 2024 vs 2023
*Compared to leading competitor full range of vision IOLs based on bench testing (white light MTF at 50 c/mm measured for 3mm & 5mm pupil in the ACE model)
** Continuous 20/25 or better based on pre-clinical bench testing for TECNIS Odyssey™
^¶ Compared to PanOptix® based on bench testing and head-to-head clinical studies of parent lens
The third-party trademarks used herein are the trademarks of their respective owners.
⁺ Compared to TECNIS SYNERGY™ and TECNIS™ Multifocal IOLs based on pre-clinical bench testing

PP 2025PP07980

¹ Data on File. DOF2023CT4007
² Data on File. DOF2019OTH4002
³ Data on File. 2024DOF4033
⁴ Data on File. DOF2023CT4023
⁵ Data on File. DOF2020CT4014 - Forte 1: A Comparative Clinical Evaluation of a New TECNIS® Presbyopia Correcting Intraocular Lens Against a PanOptix® Intraocular Lens - DEFOCUS CURVES AND VISUAL ACUITY RESULTS.
⁶ Data on File. 2024DOF4003

Media Contact:
Jamie Hall
Johnson & Johnson MedTech
[email protected]

SOURCE Johnson & Johnson MedTech